Delayed hypersensitivity reaction to loperamide: An intriguing case report with positive challenge test  by Nahas, Olga et al.
lable at ScienceDirect
Allergology International 66 (2017) 139e140Contents lists avaiAllergology International
journal homepage: ht tp: / /www.elsevier .com/locate/al i tLetter to the EditorDelayed hypersensitivity reaction to loperamide: An intriguing case
report with positive challenge testDear Editor,
Loperamide hydrochloride (Imodium®) is a symptomatic anti-
diarrheal agent used for relieving acute and chronic diarrhea. It
is an opiate derivative, which has no effects on central nervous
system. Loperamide stops diarrhea via its negative effects on intes-
tinal peristalsis and its mild antisecretory properties.1 Loperamide
is generally considered safe, but was in few cases the cause of
anaphylaxis.
We report the case of a 48 year old female patient, with no
relevant past medical or surgical history, who presented to allergy
consultation in 2008 for a potential exploration of multiple drug
allergy history. The patient described two possible immune-
mediated allergic reactions that had occurred three years ago
before, the ﬁrst during an upper respiratory tract infection with
a delayed generalized urticaria at day ﬁve of amoxicillin intake.
The second episode was particularly severe and occurred during
a gastroenteritis episode. In fact, eight to 10 h after taking diclofe-
nac, paracetamol, pantoprazole and loperamide hydrochloride, she
presented generalized urticaria, lips angioedema and dysphagia.
Symptoms resolved within 2e3 h after parenteral administration
of antihistamines and corticosteroids in the emergency depart-
ment. Skin prick tests to diclofenac and amoxicillin were negative.
Intradermal skin tests to amoxicillin and other penicillins were
also negative. Then, oral challenge tests to diclofenac and amoxi-
cillin were done and were both negative. The patient had
re-taken paracetamol and pantoprazole without allergic symp-
toms after the episode. Because loperamide was considered an un-
essential drug, it was not tested at the time and avoidance was
recommended.2
The patient returned to the allergy consultation four years after
the initial visit. Since her ﬁrst reactions, she had presented four
more episodes of generalized urticaria with lips angioedema occur-
ring every time 8e12 h after taking loperamide and requiring visits
to the emergency department. Her general practitioner prescribed
loperamide without taking care of our ﬁrst recommendation.
Despite the fact that loperamide's responsibility in these different
circumstances might have seemed obvious, we decided to perform
an allergy work up for loperamide, especially due to the intriguing
chronology; a non-immediate anaphylaxis. Skin prick tests (per-
formed with 1 tablet of loperamide 2 mg/1 ml water) were nega-
tive, allowing us to proceed to the oral drug challenge test.
Progressive incremental doses were administered till a total cumu-
lative dose of 6 mg. Due to the severity and particular chronology ofPeer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).the different episodes, we decided to keep the patient under hospi-
tal surveillance for 24 h. Eighteen hours after the beginning of oral
challenge test to loperamide, the patient developed generalized ur-
ticaria, angioedema of the tongue and lips, dysphagia and respira-
tory distress. She was treated with adrenalin, corticosteroids and
antihistamines. Respiratory symptoms resolved rapidly and cuta-
neous signs within three to 4 h.
In order to ﬁnd an alternative to loperamide, we decided to test
racecadotril, which is also an opiate derivative. Skin prick test to
racecadotril was negative and it was followed by oral negative chal-
lenge test. Since the allergy work up, the patient has taken it twice
without any allergic reaction.
Discussion
Rarely, specialized allergy explorations were done after an
anaphylactic reaction due to loperamide. Only two cases of imme-
diate IgE-mediated anaphylactic reaction to loperamide are pub-
lished. Both cases consisted in a severe clinical presentation.3,4 In
our patient, the duration before symptoms onset, eight to 10 h after
taking loperamide was too long for considering an immune type 1
mediated hypersensitivity reaction. Surprisingly, the delay of 18 h
before symptoms onset during the oral drug challenge, which is
doubled in comparison to her “in real life episodes”, lead us to
believe that other mechanisms could be involved. To the best of
our knowledge, no other similar cases have been reported in the
literature. After twenty years of experience in drug allergy work
up and more than 3000 drug provocation tests performed, our
experience is that about 95% of the reactions elicited during drug
provocation tests are either of similar or sometimes of shorter chro-
nology than that of the original case (data not published). Only
rarely did the chronology during drug provocation test exceed
the one of the initial reaction.
Hypotheses to explain the longer delay during the challenge test
before symptoms begin are: (i) a decreased gastrointestinal perme-
ability of normal mucosa and therefore delayed absorption of loper-
amide in comparisonwith infected mucosa during a gastroenteritis
episode; no data are available to support this hypothesis, but it
cannot be excluded; (ii) an intervention of others neurotransmit-
ters and mediators than those released in immune IgE-mediated
hypersensitivity; (iii) loperamide can induce hypersensitivity
symptoms via opiates induced histamine release mechanism; in
fact, this hypothesis is unlikely since the piperidine and phenylpi-
peridine group of opioid receptor agonists includes fentanyl, diphe-
noxylate, and loperamide that are structurally very different fromvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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histamine release.5,6
We realized a review of the French PharmacoVigilance data-
bases. We found 73 cases with a possible acute allergic reaction
to loperamide. None of these reactions were explored by allergy
skin tests, or by drug provocation tests. In the majority of these re-
ports, loperamide was taken in the context of acute gastroenteritis.
Then, it is reasonable to question, whether the viral infection and/
or the damaged digestive mucosa would change the absorption
and/or metabolism of loperamide; or if viral infection can promote
faster digestive neurotransmitters release inducing hypersensitiv-
ity symptoms (acetylcholine, histamine…).Conﬂict of interest
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